Bernzott Capital Advisors Has $3.55 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bernzott Capital Advisors lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,580 shares of the medical equipment provider’s stock after selling 6,432 shares during the quarter. Bernzott Capital Advisors’ holdings in Zimmer Biomet were worth $3,547,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ZBH. Dunhill Financial LLC boosted its stake in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $28,000. Bangor Savings Bank acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $31,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $35,000. Finally, Quarry LP acquired a new stake in Zimmer Biomet in the 2nd quarter valued at $53,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 2.2 %

NYSE ZBH opened at $108.86 on Friday. The stock has a 50-day simple moving average of $107.81 and a 200 day simple moving average of $107.96. The company has a market capitalization of $21.67 billion, a PE ratio of 20.70, a P/E/G ratio of 1.79 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the firm earned $1.65 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. Zimmer Biomet’s payout ratio is 18.25%.

Analysts Set New Price Targets

ZBH has been the topic of several recent analyst reports. Evercore ISI decreased their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Barclays reduced their price objective on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Raymond James reduced their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company boosted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.